Brain Cancer

11 protocols meet the specified criteria.

• A051901

  Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

• A072201

  Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs SOC in Patients with Recurrent Glioblastoma

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• A211901

  Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

• COG-ACNS1833

  A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

• EAF223

  GABLE: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• F8394-201

  A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

• GRAIL-MA-002

  REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

• NRG-BN011

  A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

• NRG-CC014

  Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)